Press Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis...
Communiqué de presse : Sanofi et Teva annoncent une collaboration exclusive pour le traitement des maladies inflammatoires de l'intestin...
Press Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli Sanofi announces...
Communiqué de presse : La FDA accorde un examen prioritaire à Dupixent® (dupilumab) pour le traitement de l’œsophagite à éosinophiles de...
Communiqué de presse : ALTUVIIIO® une fois par semaine, une nouvelle classe de facteur VIII de remplacement, approuvé au Japon pour le...
Press Release: Availability of the Q3 2023 Memorandum for modelling purposes Availability of the Q3 2023 Memorandum for modelling purposes...
Press Release: Sanofi supporting vulnerable communities as part of commitment to social impact and fight against climate change Sanofi...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.